To access a live webcast of the presentation, please visit the Investors, Events and Presentations section of the Company’s website at www.sellaslifesciences.com. A replay of the webcast will be available on the Company’s website following the live presentation. SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications.
NEW YORK, Dec. 04, 2019 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...
A look at the shareholders of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) can tell us which group is most powerful...
The final data show a median overall survival (OS) of 21.0 months, at a median follow-up of 30.8 months, in patients receiving GPS therapy compared to 5.4 months in the AML CR2 patients treated with best standard care, a statistically significant difference (p-value < 0.02). Final analysis also showed that GPS therapy continued to be well-tolerated throughout the study.
NEW YORK, Feb. 10, 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the.
- Phase 3 Galinpepimut-S (GPS) Acute Myeloid Leukemia (AML) Study Open for Enrollment and Patient Screening Underway - - Regulatory Feedback Regarding.
NEW YORK, Jan. 06, 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the.
NEW YORK, Feb. 14, 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the.
-- Study Open for Enrollment and Patient Screening Underway -- NEW YORK, Jan. 08, 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a.
In the shareholder letter Angelos Stergiou, MD, ScD h.c., SELLAS’ President & Chief Executive Officer, addresses the Company's product development, anticipated clinical milestones, and operational plans for 2020. Although we are now all living through this COVID-19 pandemic, I hope to convey a theme of growth and transformation at SELLAS as we are further advancing our clinical programs and remain diligent in our business development and licensing efforts.
NEW YORK, March 13, 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the.
NEW YORK, March 18, 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the.
The Phase 1 open-label clinical study is being conducted by Memorial Sloan Kettering Cancer Center (MSK) and is enrolling patients with MPM who harbor relapsed or refractory disease after having received frontline, standard-of-care multimodality therapy. The principal investigator for the study is Marjorie G. Zauderer, MD, Co-Director, Mesothelioma Program and Associate Attending Physician in the Thoracic Oncology Service, Department of Medicine at MSK.
Independent Data Monitoring Committee (DMC) to Review and Evaluate Patient Safety and Efficacy Data for Pivotal Phase 3 Trial of Galinpepimut-S in Patients with Acute Myeloid.
Steering Committee to Provide Scientific Oversight and Guidance for Pivotal Phase 3 Trial of Galinpepimut-S in Patients with Acute Myeloid Leukemia in Second RemissionHagop.
NEW YORK, May 14, 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development.
If you own shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) then it's worth thinking about how it contributes...
NEW YORK, Jan. 09, 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the.
The date and time of the Annual Meeting, as disclosed in the previously distributed Notice of the Annual Meeting and Definitive Proxy Statement (the "Notice and Proxy Statement"), has not changed. Stockholders of record and registered beneficial owners as of the close of business on April 13, 2020 will be able to vote and ask questions during the meeting through the online platform. Stockholders will not be able to attend the Annual Meeting in person.